Page 1

Kidney Cancer Therapeutics & Diagnostics Market The market is anticipated to record a CAGR of 10.5% for the period 2018-2023. One of the frequent urologic cancers is kidney cancer. The rate of carcinoma of renal cells has gradually increased over the past few years. Global Kidney Cancer Diagnostics and Therapeutics Market growth is driven mainly by factors such as rising aging population, lifestyle changes such as increased alcohol intake and disproportionate smoking, and government policies to better care for kidney cancer.

Increasing Number of Kidney Cancer Cases: The need for early identification of these diseases will lead to growth in the market for therapy and diagnostics of kidney cancer. Increasing detection of presymptomatic tumors through imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain upward trends in renal cell carcinoma occurrence. Other factors, such as increased pharmaceutical companies R&D expenditure and increased incidences of chronic disease and aging population, will lead to market growth over the forecast period. Get a Free Sample Copy of this Report @ High Cost Associated with Treatment:

Kidney cancer drugs are very expensive because of all the regulatory studies involved in obtaining approvals to move findings from development stage to market for commercial use. With the introduction of an approved new drug, it is possible to view the older drug, which is now generic, as a substandard form of treatment, adding to the situation. In cases where regulatory bodies, such as FDA, may want to consider taking into account economy and costeffectiveness, there are certain legal barriers to prevent them from doing so when approving new drugs. Because most cases of kidney cancer are diagnosed at the end stage, the seriousness of cancer and its diagnosis plays an important role in the patients and physicians decision to pay the high treatment price even for marginal outcome improvements. This can act as a restrictive factor in the growth of the therapeutic and diagnostic market for kidney cancer. Other factors such as low success rate in cancer drug clinical trials and regulatory issues will result in market slowdown. North America to Dominate the Market: North America holds the largest share of the global kidney cancer therapy and diagnostics market. An increasing number of cases of kidney cancer and other kidney diseases is the major driving factor in this region’s growth. However, in the forecast period, Asia-Pacific is expected to be the most rewarding market. Growing patient awareness, lower drug production costs, and rising patient base with disease, such as renal cell carcinoma, are expected to drive market growth in this region. Get More Information about this Report and TOC @ Key Market Developments: November 2017 — The U.S. Food and Drug Administration today approved Sutent sunitinib malate for adjuvant treatment of adult patients with high risk of kidney cancer renal cell carcinoma returning after removal nephrectomy — Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories.

TABLE OF CONTENT: CHAPTER 1 INTRODUCTION 1.1. Market Definition 1.2. Executive Summary 1.3. The Scope of the Study CHAPTER 2 RESEARCH METHODOLOGY 2.1. Secondary Research 2.2. Primary Research 2.3. Analytic Tools and Model 2.4. Economic Indicator 2.4.1. Base Year, Base Currency, Forecasting Period 2.5. Expert Validation 2.6. Study Timeline CHAPTER 3 MARKET ANALYSIS 3.1. Industry Value Chain Analysis 3.2. Porters Five Force Analysis 3.2.1. Bargaining Power of Buyers 3.2.2. Bargaining Power of Suppliers 3.2.3. Threats of Substitutes 3.2.4. Threats of New Entrants 3.2.5. Degree of Competition 3.3. PESTLE Analysis 3.3.1. Political 3.3.2. Economical 3.3.3. Social 3.3.4. Technological 3.3.5. Legal 3.3.6. Environmental 3.4. SWOT Analysis

3.4.1. Strengths 3.4.2. Weakness 3.4.3. Opportunities 3.4.4. Threats 3.5. Y-O-Y Analysis CHAPTER 4 MARKET DYNAMICS 4.1. Market Drivers 4.1.1. Increased number of cases of kidney cancer 4.1.2. Increased pharmaceutical companies R&D expenditure 4.1.3. Increasing populations of chronic diseases and aging 4.2. Market Restraints 4.2.1. High cost related to treatment 4.2.2. Low success rate for cancer drugs in clinical trails 4.2.3. Issues of regulation 4.3. Market Opportunities 4.4. Key Challenges CHAPTER 5 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – BY CANCER TYPE 5.1. Introduction 5.2. Renal Cell Carcinoma 5.3. Clear Cell Renal Cell Carcinoma 5.4. Papillary Renal Cell Carcinoma 5.5. Chromophobe Renal Cell Carcinoma 5.6. Others CHAPTER 6 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – BY THERAPY 6.1. Introduction 6.2. Afinitor 6.3. Avastin 6.4. Inlyta 6.5. Nexavar 6.6. Proleukin 6.7. Votrient 6.8. Sutent CHAPTER 7 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – BY DIAGNOSTICS 7.1. Introduction 7.2. Biopsy 7.3. Intravenous pyelogram 7.4. CT Scan 7.5. Nephro-ureteroscopy

7.6. Ultrasound 7.7. Others Enquire Now… @ CHAPTER 8 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – BY END USERS 7.1. Introduction 7.2. Hospitals 7.3. Pharmaceutical Labs 7.4. Genomics Laboratories 7.5. Others CHAPTER 9 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – BY GEOGRAPHY 9.1. Introduction 9.2. North America 9.2.1. U.S. 9.2.2. Canada 9.2.3. Mexico 9.2.4. Costa Rica 9.3. South America 9.3.1. Brazil 9.3.2. Argentina 9.3.3. Chile 9.3.4. Columbia 9.3.5. Others 9.4. Europe 9.4.1. U.K. 9.4.2. Germany 9.4.3. France 9.4.4. Italy 9.4.5. Spain 9.4.6. Russia 9.4.7. Netherlands 9.4.8. Switzerland 9.4.9. Poland 9.4.10. Others 9.5. APAC 9.5.1. China 9.5.2. Japan

9.5.3. India 9.5.4. South Korea 9.5.5. Australia & New Zealand 9.5.6. Malaysia 9.5.7. Singapore 9.5.8. Others 9.6. Middle East & Africa 9.6.1. UAE 9.6.2. Saudi Arabia 9.6.3. Iran 9.6.4. Iraq 9.6.5. Qatar 9.6.6. South Africa 9.6.7. Algeria 9.6.8. Morocco 9.6.9. Nigeria 9.6.10. Egypt 9.6.11. Others CHAPTER 10 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET - COMPANY PROFILES 10.1. Abbott Laboratories 10.2. Amgen 10.3. Bayer Healthcare 10.4. Cerulean Pharma 10.5. F. Hoffmann-La Roche 10.6. Genentech 10.7. GlaxoSmithKline 10.8. Novartis 10.9. Pfizer 10.10. Seattle Genetics CHAPTER 11 KIDNEY CANCER THERAPEUTICS & DIAGNOSTICS MARKET – COMPETITIVE LANDSCAPE 11.1. Market Share Analysis 11.2. Strategies adopted by top companies 11.3. Mergers, Acquisitions, Collaborations & Agreements CHAPTER 12 MARKET INSIGHTS 12.1. Industry Experts Insights 12.2. Analysts Opinions

12.3. Investment Opportunities CHAPTER 13 APPENDIX 13.1. List of Tables 13.2. List of Figures About Us: Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision-making process. We have a huge database of market research reports & company profiles across the globe. We offer premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Planet Market Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, & industry experts which provide you deeper penetration of market research industry ensuring you will receive the most reliable and up to date research data available. Name: Jennifer Daniel Email-Id: US: +1-716-2260907 UK: +447441952057 Organization: Planet Market Reports

Profile for william joe

Kidney Cancer Therapeutics & Diagnostics Market Forecast  

The market is anticipated to record a CAGR of 10.5% for the period 2018-2023. One of the frequent urologic cancers is kidney cancer. The rat...

Kidney Cancer Therapeutics & Diagnostics Market Forecast  

The market is anticipated to record a CAGR of 10.5% for the period 2018-2023. One of the frequent urologic cancers is kidney cancer. The rat...

Profile for willjo936